<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00214916</url>
  </required_header>
  <id_info>
    <org_study_id>PICU-insulin study</org_study_id>
    <nct_id>NCT00214916</nct_id>
  </id_info>
  <brief_title>Tight Glycemic Control With Intensive Insulin Therapy in PICU</brief_title>
  <official_title>KULeuven Intensive Insulin Study in Pediatric Intensive Care Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Greet Van den Berghe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a previous study, the investigators showed that tight blood glucose control with insulin
      during intensive care reduced morbidity and mortality in adult intensive care patients.
      Whether this intervention also improves prognosis of pediatric intensive care patients
      remains unknown. The current prospective, randomized, controlled study will asses the impact
      of intensive insulin therapy on outcome of patients in a pediatric intensive care unit. On
      admission patients will be randomly assigned to either strict normalization of blood glucose
      according age adjusted values or the conventional approach, in which insulin infusion is
      initiated only when blood glucose exceeds 215 mg/dl to maintain blood glucose levels between
      180-200 mg/dl.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study type: Interventional study

      Study design: single centre, prospective, randomized, active control, parallel assignment,
      efficacy study
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of inflammation</measure>
    <time_frame>during ICU stay to day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>duration of dependency on intensive care (days in ICU)</measure>
    <time_frame>time in ICU</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration mechanical ventilation</measure>
    <time_frame>during time in ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failure/need for organ support</measure>
    <time_frame>during time in ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality (safety endpoint)</measure>
    <time_frame>during time in ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>long-term follow-up study : focus on neurocognitive development (ethical approval granted)</measure>
    <time_frame>3 years (+/- 6 months) after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">700</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional insulin therapy (using Actrapid IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intensive insulin therapy (using actrapid IV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intensive insulin therapy (Actrapid IV to normoglycemia)</intervention_name>
    <description>intensive insulin therapy (Actrapid IV in continuous infusion to age-dependent normoglycemia)</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Actrapid IV to normoglycemia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conventional insulin therapy (Actrapid IV only for excessive hyperglycemia)</intervention_name>
    <description>conventional insulin therapy (Actrapid IV in continuous infusion only to treat blood glucose levels exceeding 220 mg/dl)</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Actrapid IV only for excessive hyperglycemia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children admitted to the pediatric intensive care unit and anticipated to require
             intensive care for at least 24 hours

        Exclusion Criteria:

          -  Expected stay &lt; 24 hours

          -  Therapy restriction upon admission

          -  No informed consent

          -  Other study enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greet Van den Berghe, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Catholic University Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dep Intensive Care Medicine University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 Nov 8;345(19):1359-67.</citation>
    <PMID>11794168</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2005</study_first_submitted>
  <study_first_submitted_qc>September 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Katholieke Universiteit Leuven</investigator_affiliation>
    <investigator_full_name>Greet Van den Berghe</investigator_full_name>
    <investigator_title>Head of Dept and laboratory of Intensive Care Medicine</investigator_title>
  </responsible_party>
  <keyword>Tight glycemic control with</keyword>
  <keyword>intensive insulin treatment</keyword>
  <keyword>versus conventional glycemic control</keyword>
  <keyword>in infant or child in ICU</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

